These investigations demonstrated that the combination of SRE and anti-PD-1 antibodies successfully suppressed tumor growth by improving CD8+ T cell infiltration with antitumor immunity in the humanized PD-1 mouse model. The gene discussed is CD8A; the disease is neoplasm.